Asset Details
Do you wish to reserve the book?
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Do you wish to request the book?
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
2022
Overview
Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer, with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently, the clinical effectiveness of OV as monotherapy remains limited, and thus investigators have been exploring various combinations with other anti-cancer agents and demonstrated improved therapeutic efficacy. As cancer cells have evolved to alter key signaling pathways for enhanced cell proliferation, cancer progression and metastasis, these cellular and molecular changes offer promising targets for rational cancer therapy design. In this regard, key molecules in relevant signaling pathways for cancer cells or/and immune cells, such as EGFR-KRAS (e.g., KRAS
G12C
), PI3K-AKT-mTOR, ERK-MEK, JAK-STAT, p53, PD-1-PD-L1, and epigenetic, or immune pathways (e.g., histone deacetylases, cGAS-STING) are currently under investigation and have the potential to synergize with OV to modulate the immune milieu of the tumor microenvironment (TME), thereby improving and sustaining antitumor immunity. As many small molecule modulators of these signaling pathways have been developed and have shown strong therapeutic potential, here we review key findings related to both OV-mediated immunotherapy and the utility of small molecule modulators of signaling pathways in immuno-oncology. Then, we focus on discussion of the rationales and potential strategies for combining OV with selected modulators targeting key cellular signaling pathways in cancer or/and immune cells to modulate the TME and enhance antitumor immunity and therapeutic efficacy. Finally, we provide perspectives and viewpoints on the application of novel experimental systems and technologies that can propel this exciting branch of medicine into a bright future.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
1-Phosphatidylinositol 3-kinase
/ Antigens
/ Biomedical and Life Sciences
/ Cancer
/ Histones
/ Humans
/ Kinases
/ Mitogen-Activated Protein Kinase Kinases
/ Oncology
/ Oncolytic Viruses - genetics
/ Phosphatidylinositol 3-Kinases
/ Programmed Cell Death 1 Receptor
/ Proto-Oncogene Proteins c-akt
/ Proto-Oncogene Proteins p21(ras)
/ Review
/ TOR Serine-Threonine Kinases
/ Tumor Suppressor Protein p53
/ Tumors
/ Vaccines
/ Viruses
